We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+30.86%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$57.5M
AUM Growth
+$2.92M
Cap. Flow
-$6.39M
Cap. Flow %
-11.12%
Top 10 Hldgs %
78.54%
Holding
23
New
4
Increased
9
Reduced
7
Closed
3

Top Buys

1
FOLD
Amicus Therapeutics
FOLD
+$2.63M
2
IPXL
Impax Laboratories, Inc.
IPXL
+$2.52M
3
PTCT icon
PTC Therapeutics
PTCT
+$2.12M
4
AERI
Aerie Pharmaceuticals
AERI
+$1.47M
5
NVCR icon
NovoCure
NVCR
+$1.43M

Top Sells

1
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.19M
2
NVRO
NEVRO CORP.
NVRO
+$3.47M
3
ALR
Alere Inc
ALR
+$2.66M
4
DGX icon
Quest Diagnostics
DGX
+$2.53M
5
LLY icon
Eli Lilly
LLY
+$2.08M

Sector Composition

1 Healthcare 77.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$6.52B
$7.95M 13.83%
567,683
+261,033
+85% +$2.12M
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
$5.69M 9.89%
150,651
+66,625
+79% +$1.47M
BIO icon
3
Bio-Rad Laboratories Class A
BIO
$8.14B
$5.03M 8.74%
30,687
-342
-1% -$51.9K
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$4.58M 7.96%
618,317
+388,691
+169% +$2.63M
CNC icon
5
Centene
CNC
$32.8B
$4.54M 7.9%
135,712
-28,558
-17% -$992K
IPXL
6
DELISTED
Impax Laboratories, Inc.
IPXL
$3.89M 6.76%
164,156
+93,921
+134% +$2.52M
UNH icon
7
UnitedHealth
UNH
$387B
$3.88M 6.75%
27,728
+4,080
+17% +$571K
INCY icon
8
Incyte
INCY
$23.4B
$3.53M 6.13%
37,407
+11,897
+47% +$1M
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.5B
$3.43M 5.96%
28,229
-11,311
-29% -$1.52M
LLY icon
10
Eli Lilly
LLY
$1.05T
$2.65M 4.61%
33,029
-25,936
-44% -$2.08M
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.2B
$1.91M 3.31%
37,644
+6,973
+23% +$347K
SGYP
12
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.87M 3.25%
339,068
+40,878
+14% +$191K
EW icon
13
Edwards Lifesciences
EW
$49.3B
$1.68M 2.92%
41,724
-43,086
-51% -$1.62M
NVCR icon
14
NovoCure
NVCR
$1.84B
$1.34M 2.33%
+157,176
New +$1.43M
NVRO
15
DELISTED
NEVRO CORP.
NVRO
$1.27M 2.21%
12,161
-38,472
-76% -$3.47M
LKFT
16
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.96B
$404K 0.7%
+6,250
New +$352K
DGX icon
17
Quest Diagnostics
DGX
$23.3B
$398K 0.69%
4,700
-30,143
-87% -$2.53M
GKOS icon
18
Glaukos
GKOS
$9.2B
$386K 0.67%
+10,233
New +$339K
PCRX icon
19
Pacira BioSciences
PCRX
$1.01B
– –
-41,707
Closed -$1.41M
TEVA icon
20
Teva Pharmaceuticals
TEVA
$37.3B
– –
-83,502
Closed -$4.19M
ALR
21
DELISTED
Alere Inc
ALR
– –
-63,905
Closed -$2.66M

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Asymmetry Capital Management held 23 positions worth $57.5M, up 5.4% from $54.6M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Asymmetry Capital Management withdrew a net $6.39M in Q3 2016, closing 3 positions and reducing 7 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $4.19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 91% a quarter earlier.

Against the trend, Asymmetry Capital Management opened a new position in NovoCure worth $1.34M.

  • Asymmetry Capital Management's largest Q3 2016 buy was NovoCure: 157,176 shares worth $1.34M.
  • Asymmetry Capital Management added most to Amicus Therapeutics in Q3 2016, an estimated $2.63M increase.
  • Asymmetry Capital Management's biggest Q3 2016 reduction was NEVRO CORP., cutting an estimated $3.47M.
  • Asymmetry Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $4.19M.
  • Asymmetry Capital Management's ten largest holdings make up 79% of its $57.5M portfolio in Q3 2016.
  • Asymmetry Capital Management opened 4 new positions and closed 3 in Q3 2016.
  • Asymmetry Capital Management's portfolio value rose 5.4% quarter-over-quarter to $57.5M.

Based on Asymmetry Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.